BLUEPRINT MEDICINES
PharmaBLUEPRINT MEDICINES is a pharmaceutical company focused on Oncology, Gastroenterology, Metabolic. Key products include AYVAKIT.
FDA Novel Drug Designations
(2020)BLUEPRINT MEDICINES at a Glance
- Leading 6 drug targets across portfolio
- Fast trial execution (31 months median completion)
BLUEPRINT MEDICINES's Key Drugs
BLUEPRINT MEDICINES's core commercial portfolio centers on AYVAKIT, GAVRETO, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
BLUEPRINT MEDICINES's Recent FDA Approvals
New NDA/BLA approvals for BLUEPRINT MEDICINES over the last two years — novel drugs only, excluding generics and label supplements.
BLUEPRINT MEDICINES's Therapeutic Areas
BLUEPRINT MEDICINES's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BLUEPRINT MEDICINES's Top Competitors
BLUEPRINT MEDICINES's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Takeda, and ASTELLAS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BLUEPRINT MEDICINES Pipeline Snapshot
BLUEPRINT MEDICINES has 16 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 15 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/1 completed
- • Speed: 31 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges